AKT Combination Increased PFS in Metastatic HR-Positive/HER2-Negative Breast Cancer

By News Health
3 days Ago

(MedPage Today) — CHICAGO — Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 inhibition, a randomized…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115871

Author :

Publish date : 2025-06-03 15:20:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Women find other women’s faces even more attractive than men do

GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns

Experts Suggest NHS Heart Risk Checks from Age 25

Experimental MS Drug Nearly Eliminates Disease Activity

Man Wakes Up During Organ Retrieval; Biden's Doc Subpoenaed; Oz: 'Prove You Matter'

Which Tx Combo Is Best for HER2+ Breast Cancer?